相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Tumour Suppressor CYLD Is Required for Clathrin-Mediated Endocytosis of EGFR and Cetuximab-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma
Rin Liu et al.
CANCERS (2022)
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Yan Peng et al.
FRONTIERS IN ONCOLOGY (2022)
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne P. Robichaux et al.
NATURE (2021)
The MEK/ERK Network as a Therapeutic Target in Human Cancer
Renee Barbosa et al.
MOLECULAR CANCER RESEARCH (2021)
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Xin Cao et al.
DRUG RESISTANCE UPDATES (2020)
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy
Yuan Yuan et al.
CELL BIOLOGY INTERNATIONAL (2020)
Relationship between clinicopathological characteristics and CYLD expression in patients with cholesteatoma
Shunsuke Miyake et al.
PLOS ONE (2020)
Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines from a Patient-Derived Xenograft Mouse Model
Kulthida Vaeteewoottacharn et al.
CELLS (2019)
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
Seiji Okada et al.
CELLS (2019)
Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma
Naoki Suenaga et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Loss of CYLD promotes cell invasion via ALK5 stabilization in oral squamous cell carcinoma
Satoru Shinriki et al.
JOURNAL OF PATHOLOGY (2018)
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2)
Dashan Ai et al.
BMJ OPEN (2018)
Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer
Yoshifumi Matsumoto et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2017)
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
Zuyao Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Toshimitsu Yamaoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Cylindromatosis Tumor Suppressor Protein (CYLD) Deubiquitinase is Necessary for Proper Ubiquitination and Degradation of the Epidermal Growth Factor Receptor
Virginia Sanchez-Quiles et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
EGFR tyrosine kinase inhibitors differentially affect autophagy in head and neck squamous cell carcinoma
Jinyang Cai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Patient-derived xenografts: a relevant preclinical model for drug development
Luca Pompili et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC
Yu Nakamura et al.
MOLECULAR CANCER THERAPEUTICS (2016)
miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD
Mingxia Zhu et al.
MOLECULAR MEDICINE REPORTS (2016)
Mechanisms of Invasion in Head and Neck Cancer
Lizandra Jimenez et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway
Yuichi Ohnishi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Hematopoietic stem cell quiescence and function are controlled by the CYLD-TRAF2-p38MAPK pathway
Melania Tesio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway
Alejandra Tomas et al.
NATURE COMMUNICATIONS (2015)
Clinical significance of CYLD downregulation in breast cancer
Mitsuhiro Hayashi et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy
Jianying Guo et al.
ONCOTARGET (2014)
Clinical Approval Success Rates for Investigational Cancer Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma
Lai-ping Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells
Daisuke Takiuchi et al.
PANCREATOLOGY (2013)
Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD
Kensei Komatsu et al.
NATURE COMMUNICATIONS (2013)
CYLD downregulation is correlated with tumor development in patients with hepatocellular carcinoma
Hiroki Kinoshita et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis
Ludovic C. Gillet et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
A Crosstalk between the Smad and JNK Signaling in the TGF-β-Induced Epithelial-Mesenchymal Transition in Rat Peritoneal Mesothelial Cells
Qinghua Liu et al.
PLOS ONE (2012)
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt
Jae Hyang Lim et al.
NATURE COMMUNICATIONS (2012)
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status
Shan Liu et al.
LUNG CANCER (2011)
GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma
S. Kuphal et al.
ONCOGENE (2011)
CYLD: a tumor suppressor deubiquitinase regulating NF-kappa B activation and diverse biological processes
S-C Sun
CELL DEATH AND DIFFERENTIATION (2010)
Loss of the Tumor Suppressor CYLD Enhances Wnt/β-Catenin Signaling through K63-Linked Ubiquitination of Dvl
Daniele V. F. Tauriello et al.
MOLECULAR CELL (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma
Ramin Massoumi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Unbiased Quantitation of Escherichia coli Membrane Proteome Using Phase Transfer Surfactants
Takeshi Masuda et al.
MOLECULAR & CELLULAR PROTEOMICS (2009)
Global epidemiology of oral and oropharyngeal cancer
Saman Warnakulasuriya
ORAL ONCOLOGY (2009)
Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling
Tomoaki Koga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis
Takeshi Masuda et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Tumor Suppressor CYLD Acts as a Negative Regulator for Non-Typeable Haemophilus influenza-Induced Inflammation in the Middle Ear and Lung of Mice
Jae Hyang Lim et al.
PLOS ONE (2007)
Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections
Jae Hyang Lim et al.
IMMUNITY (2007)
The bacterium, nontypeable Haemophilus influenzae, enhances host antiviral response by inducing Toll-like receptor 7 expression -: Evidence for negative regulation of host antiviral response by CYLD
Akihiro Sakai et al.
FEBS JOURNAL (2007)
Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips
Juri Rappsilber et al.
NATURE PROTOCOLS (2007)
Mutations in the NF-κB signaling pathway:: implications for human disease
G. Courtois et al.
ONCOGENE (2006)
The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7
H Yoshida et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer
G Giaccone
JOURNAL OF CLINICAL ONCOLOGY (2005)
Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-β-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo
SK Kamaraju et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
NF-κB is essential for induction of CYLD, the negative regulator of NF-κB -: Evidence for a novel inducible autoregulatory feedback pathway
H Jono et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Negative regulation of JNK signaling by the tumor suppressor CYLD
W Reiley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
TR Brummelkamp et al.
NATURE (2003)
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
A Kovalenko et al.
NATURE (2003)
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
E Trompouki et al.
NATURE (2003)
Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics
J Rappsilber et al.
ANALYTICAL CHEMISTRY (2003)
Identification of the familial cylindromatosis tumour-suppressor gene
GR Bignell et al.
NATURE GENETICS (2000)
Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:: three meta-analyses of updated individual data
JP Pignon et al.
LANCET (2000)
分享论文
